Welcome to YLOAN.COM
yloan.com » analysis » Hepatitis C (hcv) Market Forecast & Drugs Pipeline Analysis To 2016
Online Business Site Promotion Web misc Affiliate-Revenue Auctions Audio-Streaming Autoresponders Blogging-Rss Email-Marketing Ezine-Publishing Forums Internet-Marketing List-Building PPC-Advertising Podcasting SEO Spam-Blocker Traffic-Building Video-Streaming Web-Design Web-Development Web-Hosting Domain Name soreness web analysis vinyl mlm searching media info spyware access microsoft outlook farmville

Hepatitis C (hcv) Market Forecast & Drugs Pipeline Analysis To 2016

Hepatitis C virus drug market is experiencing a dramatic near-term growth

, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.

Pegasys, Copegus and Pegintron were the only obtainable drugs in Hepatitis C drug market till May 2011. Pegasys always had more revenue generation in any year compared to Pegintron and is also expected to have higher revenue in future till 2016. However by the end of May 2011, the dynamics of the market has changed after the launch of Incivek and Victrelis. Incivek sale has grown quickly and it garnered around US$ 400 Million by end of 3rd quarter 2011. It is expected that Incivek sales will be slightly less than US$ 4 Billion by 2015. On the other hand Victrelis, which was approved a week before Incivek, is moving along a slower adoption curve. Victrelis has lost its grip into the market and reaped only US$ 31 Million sales by the end of 3rd quarter 2011.

In respect of these there are many other pipeline drugs, which are currently in clinical trial Phase II or Phase III and expected to be launched by 2014. Pipeline drugs like Setrobuvir (ANA 598), RG-7128, TMC - 435 and Danoprevir are going to be the next game changers in the Hepatitis C drug market. Renub Research report entitled Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape, launched HCV drugs present and future performance, yet to be launched HCV drugs forecast. Most importantly, the report provides valuable insight into the pipeline products within the global Hepatitis C sector.

What We Have Achieved in this Report


Comprehensive situation analysis of the Global Hepatitis C drug market and its dynamics.

Identifying all available drugs, pipeline drugs and their position in clinical trials and quantifying their current and future market potential.

Providing a robust long range value forecast for all available drugs, pipeline drugs and their position in clinical trial.

Providing an understanding of key drivers and restraints and their impact on current and future market scenario.

Competitive Landscape

This section covers the key facts about the major companies that play an important role in Hepatitis C drug market. The companies analyzed in this section are Merck, Vertex Pharmaceuticals, Roche, Pharmasset, Anadys Pharmaceuticals. All the companies have been analyzed from two points of views.

1) Strength of the company in Hepatitis C drug market

2) Weakness of the company in Hepatitis C drug market.

Data Sources

This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Renub Research team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Click here to view the report details: http://renub.com/reports/showdetails.aspx?id=55

For more information visit: http://www.renub.com/

Related Reports: http://renub.com/reports/showdetails.aspx?id=53

http://renub.com/reports/showdetails.aspx?id=52

Contact Us

Ankit Mishra

Relationship Manager

Sales & Marketing Div

Renub Research


Email: info@renub.com

Phone: +1-678-302-0700 (USA) +91-120-254-5750, +91-120-4219-822(India)

Web: http://www.renub.com/

by: Renub Research
Nursing Profession A Thorough Analysis For Aspiring Nurses Book A Hair Analysis Package, Grab Your Chance To Win A Car Blood Test Analysis Interpretation An Overview Of Hair Analysis Analysis Of A Spy Pen Why Stock Market Technical Analysis Is An Essential Part Of Trading Digital Video Gait Analysis Offers Improved Visual Tool For Patients That Structural Analysis Of Buildings Works? Whether Go To Buy Or Sale Location Analysis Required 52 Week Lows A Realistic Analysis To Determine Stocks To Buy Trading Technical Analysis Multi-function Adsl/adsl2+ Tester Provides Histogram Analysis An Analysis Of Social E-commerce
print
www.yloan.com guest:  register | login | search IP(216.73.216.110) California / Anaheim Processed in 0.023327 second(s), 7 queries , Gzip enabled , discuz 5.5 through PHP 8.3.9 , debug code: 54 , 4204, 354,
Hepatitis C (hcv) Market Forecast & Drugs Pipeline Analysis To 2016 Anaheim